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The Insulin-Like Growth Factor System
Derek Le Roith
Diabetes Branch, National Institutes of Health, Bethesda, Maryland, USA
The insulin-like growth factor (IGF) system in ubiqui-
tous and plays a role in every tissue of the body. It is com-
prised of ligands, receptors and binding proteins, each with
speciﬁc functions. While it plays an essential role in em-
bryonic and post-natal development, the IGF system is also
important in normal adult physiology. There are now nu-
merous examples of diseases such as diabetes, cancer, and
malnutritioninwhichtheIGFsystemisamajorplayerand,
notsurprisingly,thereareattemptstoaffectthesedisorders
by manipulating the system.
Keywords Binding Proteins; Insulin-Like Growth Factors; Recep-
tors; Signaling Pathways
INTRODUCTION
The insulin-like growth factor (IGF) system includes three
ligands (insulin, IGF-I, and IGF-II), three receptors (the insulin
receptor [IR], the IGF-I receptor [IGF-IR], and the mannose-
6-phosphate IGF-II receptor [M6P/IGF-IIR]), as well as six
IGF-binding proteins (IGFBPs). This family of growth fac-
tors has been extensively studied, because of its critical roles
in both normal physiology and in various disease states, such
as cancer, diabetes, and nutritional status abnormalities. The
various components of the IGF family are widely expressed,
and other important functions of this system are rapidly being
discovered.
This article will present an overview of the IGF system, in-
cluding the biological functions of its various components and
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how the expression levels of these components are controlled.
The major emphasis will be on more recent ﬁndings, with par-
ticular focus on aberrations of the system, because many excel-
lent reviews have previously covered the more familiar aspects
of the IGF system (Baxter, 2000; Clemmons, 2001; Le Roith
et al., 1995; Rajaram et al., 1997; Stewart and Rotwein, 1996).
Where appropriate, aberrations of the system will be discussed
in the context of diabetes and its complications.
LIGANDS
IGF-I
Insulin-like growth factor-I (IGF-I) is expressed by most
tissues of the body. It circulates as a 70-residue single-chain
polypeptide with four domains, designated as B, C, A, and
D. In comparison, proinsulin includes the B, C, and A do-
mains, whereas mature insulin produced and secreted by the
pancreas includes only the B and A domains. Circulating IGF-
I is primarily derived from the liver, although other tissues,
such as fat, may also contribute (Yakar et al., 1999). The ma-
jor factors that regulate hepatic IGF-I biosynthesis are growth
hormone (GH), insulin, and nutritional status. Although GH
is the major factor that stimulates IGF-I expression and re-
lease, insulin and nutrients can also signiﬁcantly affect this re-
sponse (Bichell et al., 1992; Kaytor et al., 2001; Zhang et al.,
1998).
In extrahepatic tissues, IGF-I gene expression is regu-
lated by several factors in addition to GH. For example, both
prostaglandin E2 (PGE2) and parathyroid hormone (PTH) in-
creaseIGF-ImRNAlevelsinculturedosteoblasts,whereasGH
has little effect on IGF-I expression in this system (Bichell
et al., 1993). Estradiol also increases expression of IGF-I in
osteoblasts (Ernst and Rodan, 1991). Other examples include
angiotensin II regulation of IGF-I expression at the local level,
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by stimulating IGF-I production in the cardiovascular system
(Brink et al., 1999), the inducion of IGF-I mRNA during com-
pensatoryrenalgrowth(Mulroneyetal.,1992),andintheregu-
lationofskeletalmusclegrowthandrepair(reviewedbyFlorini
etal.,1996).Thyroid-stimulatinghormone(TSH)inducesIGF-
I mRNA expression in thyroid cells (Hofbauer et al., 1995). Fi-
nally, estrogen may play an important role in the local regula-
tionofIGF-Iinovariananduterinetissue(MurphyandFriesen,
1988).
Theroleofcirculating“endocrine”IGF-I(primarilyderived
from the liver) versus the local “paracrine/autocrine” IGF-I has
recently been reevaluated through the use of the tissue-speciﬁc
gene-deletion (cre-lox/P) technology (Yakar et al., 1999). In
this system, a construct including the IGF-I gene ﬂanked by
lox/P sequences was introduced into mice using homologous
recombination. In another transgenic mouse line, the recombi-
nase enzyme (cre) is expressed in the tissue of interest using a
speciﬁc promoter-enhancer element, and the two mice lines are
crossed. Using this approach, IGF-I gene expression was ab-
lated speciﬁcally in the liver of mice (Yakar et al., 1999). The
resultingmiceexhibitedcompleteabrogationofIGF-Igeneex-
pressionfromtheliverwithnormalproductioninallnonhepatic
tissues.AlthoughtotalcirculatingIGF-Ilevelswerereducedby
75% to 80% in the “liver knockout” mice, their growth and de-
velopment was apparently normal. However, the total levels of
circulating IGF-I levels were further reduced when these mice
werecrossedwithacid-labilesubunit(ALS)gene-deletedmice.
Inthecirculation,ALSformsacomplexwithIGFsandIGFBP-
3. The loss of ALS results in very low binding capacity and
protection for circulating IGFs. This double knockout animal
exhibited growth retardation, suggesting that circulating IGF-
I contributes to growth, but that local production of IGF was
also important (Yakar et al., 2002). Interestingly, these studies
revealedthatIGF-Ihasdualeffectsonbonedevelopment;circu-
lating IGF-I played a major role in bone density, whereas both
circulatingandlocalIGF-Iwereinvolvedinlinearbonegrowth.
IGF-II
Ablation of the IGF-II gene demonstrated that IGF-II plays
acriticalroleinnormalgrowthanddevelopmentinmice.From
embryonicday11onward,IGF-IIknockoutmiceexhibitedpro-
portionate growth retardation. There were no further postnatal
effects on growth in these mice, because the expression and
circulating levels of IGF-II decrease dramatically after birth in
rodents.
In contrast, the major effects of IGF-I gene ablation were
observed during the postnatal period, including severe growth
retardation, infertility, and other effects (Baker et al., 1993; Liu
etal.,1993;LiuandLeRoith,1999;Wangetal.,1999).Expres-
sion of IGF-II in cultured cells is regulated by various agents,
including follicle-stimulating hormone (FSH), chorionic go-
nadotrophin and cyclic AMP (cAMP) in ovarian cells, adreno-
corticotropichormone(ACTH)andcAMPinfetaladrenalcells,
glucocorticoids and thyroid hormone in hepatic cells, and glu-
cose in a pancreatic beta-cell line. IGF-II is also increased in
responsetoglucoseinfetalhepatocytes,andplaysanimportant
autocrine/paracrine role in skeletal muscle myoblast differen-
tiation in vitro (Stewart and Rotwein, 1996). In the circulation,
IGF-II is a 67–amino acid, single-chain polypeptide. However,
patients with certain types of tumors occasionally release “big-
IGF-II,” a larger precursor form with a 21–amino acid exten-
sion designated as the E-peptide. Big-IGF-II may cause hypo-
glycemia by interfering with the normal effect of the IGFBPs
on neutralizing circulating IGFs, thereby enabling big-IGF-II
to interact with IRs (Daughaday et al., 1988).
RECEPTORS
IR and IGF-IR
The IR and IGF-IR are products of separate genes that span
>100 kilobases and contain over 20 exons. They belong to the
membrane spanning family of tyrosine kinase receptors. These
receptors are organized into functional domains. The mature
receptor is expressed in an α2β2 conﬁguration, where two α
chainsarejoinedbydisulﬁdebonds.Theβ subunitliesentirely
within the extracellular region and contains a cysteine-rich do-
mainthatformstheprimarybindingsiteforIGFsintheIGF-IR,
whereas insulin apparently binds regions ﬂanking the cysteine-
rich domain of the IR. The β subunit includes a 24-residue
hydrophobic transmembrane domain, a short extracellular re-
gion, and a large cytoplasmic region that includes a tyrosine
kinase domain. The tyrosine kinase region is highly conserved
between the IGF-IR and the IR, sharing approximately 84%
similarity at the amino acid level. The juxtamembrane region
containsvariousmotifsthatbindtoimportantintracellularsub-
strates. The most divergent region between the two receptors is
the cytoplasmic carboxyl-terminal domain (Ulrich et al., 1985,
1986).
As a consequence of this high level of homology, hybrid re-
ceptors, comprised of an insulin αβ hemireceptor and an IGF-I
αβ hemireceptor,canformintissuesandculturedcellsexpress-
ing both the IR and the IGF-IR (Federici et al., 1997a, 1997b).
Such hybrid receptors may play a role in the divergent actions
of insulin and IGF-I. The biological response elicited by these
hybridreceptorscanvary,dependingonthespeciﬁcisoformsof
theIRthatareinvolved.TheIRexistsastwoisoformsgenerated
by alternative splicing of the IR gene that either lacks (IR-A) or
includes (IR-B) 12 amino acid residues encoded by exon 11 at
the carboxyl terminus of the IR α subunit. Hybrids comprisedIGF 207
of an IR-A hemireceptor and an IGF-IR hemireceptor bound
IGF-I, IGF-II, and insulin and exhibited cell proliferation and
migration, even in response to insulin, presumably via activa-
tion of the IGF-IR. In contrast, hybrids comprised of an IR-B
hemireceptor and an IGF-IR hemireceptor were only respon-
sivetoIGF-IbutnotIGF-IIorinsulin(Pandinietal.,2002).The
IR-A homoreceptor binds IGF-II with high afﬁnity and may be
important in the functional role of IGF-II in the fetus and in
dedifferentiated (malignant) cells (Frasca et al., 1999; Sciacca
et al., 1999).
Receptor Functioning
Najjar and coworkers identiﬁed pp120, a plasma membrane
glycoprotein,asaspeciﬁcsubstratefortheIRbutnottheIGF-IR
(Najjaretal.,1997;Sonietal.,2000).Phosphorylationofpp120
is required for its function in insulin endocytosis (Formisano
et al., 1995), and also for its inhibitory effect on the mitogenic
actions of insulin (Soni et al., 2000). Interestingly, when the
carboxyl terminus of the IGF-IR is replaced by an equivalent
region of the IR, the chimeric IGF-IR can then bind to and
phosphorylate pp120, and the effect of IGF-I on cell growth
is decreased (Soni et al., 2000). Mutation of Tyr1316 in the IR,
which is not conserved in the IGF-IR, abrogates the insulin-
induced tyrosine phosphorylation of pp120 and its ability to
suppress insulin-induced mitogenesis.
Like the IR, IGF-IRs are internalized following ligand bind-
ing and activation. Activation of the IGF-IR enhances the asso-
ciation of EHD1 with the IGF-IR and SNAP29. EHD1 belongs
toafamilyofproteinsthatcontainEHdomainsandareinvolved
informingproteincomplexesthatpromoteclathrin-coatedvesi-
cles and are involved in endocytosis. Overexpression of EHD1
in NIH-3T3 ﬁbroblasts inhibits IGF-I signaling and supports
the hypothesis that endocytosis may be a mechanism whereby
the IGF-IR signal is abrogated (Rotem-Yehudar et al., 2001).
Internalization is also affected by Gαi and β-arrestin-1, which
bindtotheIGF-IRafteractivation,andalsoenhancestheactiva-
tion of mitogen-activated protein (MAP) kinase by the IGF-IR
(Dalle et al., 2001; Lin et al., 1998).
SIGNAL TRANSDUCTION VIA IR AND IGF-IR
Common Signaling Pathways
In addition to the structural similarities of the IR and
IGF-IR, many of the intracellular signaling events that result
from ligand-induced receptor activation are remarkably simi-
lar (Cheatham and Kahn, 1995; Le Roith et al., 1995; White,
1994). The tyrosine kinase domains of the IR and IGF-IR cat-
alyze the phosphorylation of speciﬁc substrates and are critical
for IR- and IGF-IR–induced signaling (Kato et al., 1993). All
conserved tyrosine residues that are phosphorylated in the IR
in response to insulin are also phosphorylated in the IGF-IR in
response to IGF-I. Thus, the IGF-IR and IR share many sub-
strates, such as the members of the IR substrate (IRS) family
(IRS-1toIRS-4),Gab-1,andShc(Fantinetal.,1998;Lavanand
Lienhard, 1993; Patti et al., 1995; Pelicci et al., 1992; Winnay
et al., 2000). IRS-1 is the best characterized of the IRS fam-
ily members. IRS proteins and Shc contain an amino-terminal
phosphotyrosine-binding (PTB) domain that enables them to
bind to the juxtamembrane domain of the IR and IGF-IR, via
phosphotyrosinesinNPEYmotifs.IRS-1andShcarecompeti-
tive substrates that can interact with both the IR and the IGF-IR
(Sasaoka et al., 1996). Upon stimulation with insulin or IGF-I,
tyrosine-phosphorylatedIRSandShcproteinsengageinthefor-
mationofsignalingcomplexesviaphosphotyrosine-containing
bindingmotifs(YXXM)withinSrchomology2(SH2)domains
foundinmoleculeslikeGRB2(growthfactorreceptorbinding-
2 protein) (Lowenstein et al., 1992; Skolnik et al., 1993), and
the p85 regulatory subunit of phosphatidylinositol 3  kinase
(PI3K) (Backer et al., 1992). The phosphotyrosine residues on
IRS-1 form docking sites for additional signaling molecules,
including Syp (SHPTP2) (Xiao et al., 1994), Fyn (Sun et al.,
1996), Nck (Lee et al., 1993), and Crk (Beitner-Johnson et al.,
1996).
BybindingtoGRB2,IRSproteinscoupleGRB2totheIRor
IGF-IR. Shc also couples these receptors to GRB2, even more
stronglythantheIRSproteins.OnceassociatedwithShcand/or
IRSproteins,GRB2formsacomplexwiththeSonofSevenless
(SOS) p21Ras guanine nucleotide GDP/GTP exchange factor.
This causes translocation of SOS to the plasma membrane and
activationoftheRas/MAPkinasepathwayandregulationofcell
growth, differentiation, and proliferation in response to insulin
and IGF-I (Blenis, 1993; Crews and Erikson, 1993).
Activation of the IR and IGF-IR and their intracellular com-
ponents in response to ligand binding is transient and is con-
trolled by several mechanisms, including phosphorylation, de-
phosphorylation, and/or degradation of certain components.
Syp(SHPTP2,PTP-1D,orSHP-2)(Lamotheetal.,1996;Maile
and Clemmons, 2002) and PTP1B (Ravichandran et al., 2001)
are two candidate phosphotyrosine phosphatases that interact
with both the IGF-IR and IR and dephosphorylate them in re-
sponse to the ligand binding. SHIP-2 and PTEN (Butler et al.,
2002) are lipid phosphatases that play signiﬁcant roles in the
regulation of PI3K signaling in response to both IGF-I and in-
sulin. It has also been shown that phosphorylation of the serine
or threonine residues of IRS-1 (Rui et al., 2001) or degradation
of IRS-1 (Sun et al., 1999) can counterregulate the insulin or
IGF-1 response.
One of the major effects of IGF-I is to promote cell sur-
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IGF-I–mediated cell survival have been described, involving
PI3K/Akt, MAP kinase, and 14-3-3 proteins. All of these pro-
teins are associated with increases in the phosphorylation state
of the proapoptotic protein BAD (Bai et al., 1999). In neu-
ronal cells, IGF-I induced phosphorylation of the forkhead
transcription factor via a PI3K/Akt-dependent signaling path-
way, thereby inhibiting apoptosis. Furthermore, IGF-I pro-
motes transcription of the antiapoptotic bcl-2 gene, by promot-
ing phosphorylation of the cAMP response element–binding
protein (CREB) transcription factor via both the p38 stress-
activated protein kinase and PI3K/Akt pathways (Pugazhenthi
et al., 1999). The antiapoptotic effects of IGF-I are mediated
through PI3K and are also important in preventing mannitol-
induced apoptosis. Mannitol induces dephosphorylation and
degradation of FAK, apparently in response to activation of
capsases. IGF-I counteracts this effect, leading to increases in
cell adhesion and cell survival (Kim and Feldman, 2002). The
IGF-IR can promote cell spreading and cell contact with the
extracellular matrix (ECM) by interacting with RACK1, a Gβ
homologue. This interaction delays progression of the cell cy-
cle, but enhances FAK and paxillin phosphorylation, thereby
alteringintegrinsignaling(Hermantoetal.,2002).RACK1may
also modulate the antiapoptotic effects of the IGF-IR via Akt
(Kiely et al., 2002).
Receptor Cross-Talk
The insulin and IGF-I receptors do not function in isolation;
their signals affect and are affected by other receptor signaling
cascades. The IGF-IR activates heterotetrameric G proteins in
certain cell types. It has been reported that the βγ subunits of
the Gi class of G proteins can mediate IGF-I–induced activa-
tion of MAP kinase (Luttrell et al., 1995). In addition, it has
been demonstrated that the IGF-IR forms a complex with the
Gα subunit of Gi proteins (Dalle et al., 2001). Interestingly,
chronic treatment with insulin can cause heterologous desen-
sitization of the IGF-I–induced activation of MAP kinase by
down-regulation of β-arrestin-1, a molecule that plays an im-
portant role in IGF-IR internalization and activation of MAP
kinase (Dalle et al., 2002). Other examples of this type of re-
ceptor cross-talk include the estrogen receptor and the IGF-IR.
Thus, in MCF-7 breast cancer cell lines and other cell lines,
costimulation with estradiol and IGF-I can induce either addi-
tive or synergistic effects on downstream signaling pathways,
suchasPI3Kandvariouscellcycleevents(Dupontetal.,2000).
The IGF-IR interacts with the cell-cell adhesion complex that
includes E-cadherin, β-catenin, and p120 catenin. When IGF-
IR expression is reduced in MCF-7 cells by the introduction of
antisense mRNA, these cells exhibit a more malignant pheno-
type that is associated with a reduction in the cell-cell adhesion
complex.Thisisthroughttoresultfromap120catenin-induced
reduction in E-cadherin and activation of Rac and Cdc42 activ-
ity (Pennisi et al., 2002).
IGFBPs
Todate,sixIGFBPsthathavehighafﬁnityfortheIGFshave
been described (Jones and Clemmons, 1995). These proteins
arecharacterizedbytheirwell-conservedamino-andcarboxyl-
terminal domains that contain several highly conserved cys-
teine residues. IGFBPs are found both in the circulation and at
the local tissue level. In the circulation, IGFBPs act as “trans-
port proteins” for the IGFs, but at the local level they act as
modulators of IGF activity (Zapf, 1995). In the circulation, the
major proportion of IGF is bound to a 150-kDa complex that
includes IGFBP-3 and ALS, which protect the IGFs from pro-
teases and prolong their circulating half-life (Rajaram et al.,
1997). IGFBPs may also function as carrier proteins, because
other IGFBPs may contribute to a 50-kDa circulating complex
thatfacilitatesthetransferofIGFsfromthecirculationtotarget
cells.
Atthetargetcelllevel,theIGFBPshavemultipleroles;some
IGFBPs modulate the effects of the IGFs and others act inde-
pendently from the IGFs and the IGF-IR (Lalou et al., 1996).
IGFBP-induced inhibition of IGF-I action occurs when IGF-
BPs prevent the interaction of IGFs with the IGF-IR (Baxter,
2000;JonesandClemmons,1995).However,thebindingafﬁni-
ties of IGFBPs are altered by various modiﬁcations, including
phosphorylation, partial proteolysis, and attachment to the cell
surface or ECM. For example, dephosphorylation of IGFBP-1
lowers its afﬁnity for IGFs. Attachment of IGFBP-3 to the cell
surface or IGFBP-5 to the ECM lowers their respective afﬁni-
tiesforIGFs.Alloftheseeffectshavebeenproposedtoenhance
the delivery of IGFs to the IGF-IR.
The potential role of the IGFBP system that has been most
extensively studied as it relates to complications of diabetes is
its effects on nephropathy. GH and IGF-I were initially shown
to affect the diabetic kidney by increasing glomerular ﬁltration
ratesandrenalplasmaﬂow,resultinginthetypicalenlargedkid-
ney seen in patients with recent onset of diabetes (Flyvbjerg,
2000). Similar changes were seen in experimental animal mod-
els of diabetes, particularly of the type 1 variety. This change
wasassociatedwithincreasedIGF-Iconcentrationsintherenal
tissue, despite a signiﬁcant reduction in IGF-I gene expression
as measured by mRNA levels. This suggested that the IGF-I
peptide was being trapped from the circulation. Indeed, sub-
sequent studies demonstrated that both the IGF-IR and certain
IGFBPs were expressed by the kidney at higher levels than in
control animals and suggested that the IGFBPs play a critical
role in the presentation of IGF-I to its receptor and thereby en-
hanceitsbiologicalfunction(Landauetal.,1995;Werneretal.,
1990). Interestingly, somatstatin analoges have been shownIGF 209
to inhibit IGFBP gene expression in diabetic animals and to
prevent the early renal changes described above (Raz et al.,
1998).
IGFBP-1 has been reported to exhibit IGF-independent ac-
tions. When the RGD sequence was prevented from interacting
with the integrin α5β1 receptor, IGFBP-1 was unable to stim-
ulate cell migration (Jones et al., 1993). In breast cancer cells,
the binding of IGFBP-1 to integrin at the cell surface resulted
in dephosphorylation of FAK, detachment from the ECM, and
cellular apoptosis (Perks et al., 1999). A proapoptotic action of
IGFBP-3hasalsobeenreportedtobeindependentofIGF(Perks
etal.,1999a,1999b;Buttetal.,2000;Maileetal.,1999).Anum-
ber of potential IGF-independent survival-promoting effects of
IGFBP-4andIGFBP-5havebeenreported;however,themech-
anisms underlying these effects are not known (Perks et al.,
1999a). Finally, IGFBP-3 and IGFBP-5 are translocated into
the nucleus via the importin-5 subunit (Schedlich et al., 1998,
2000).Thecellularconsequencesoftheseactionsareunknown.
Nevertheless,takentogether,theseﬁndingssuggestthatvarious
IGF-I–independent actions of IGFBPs can regulate cell growth
and survival.
SUMMARY
The IGF system is ubiquitous and has multiple roles in
normal physiology and pathological states. Although it regu-
lates important functions in normal growth, development, and
differentiation of most tissues, aberrations in the IGF system
are clearly associated with various pathological conditions, in-
cluding cancer, acromegaly, growth retardation, diabetes, and
its associated complications, such as retinopathy, nephropathy,
neuropathy, and insulin resistance. Understanding the control
of expression of the various components as well as the signal
transduction pathways involved in IGF-I receptor function will
facilitatethedevelopmentofspeciﬁctherapeuticmodalitiesfor
these and other disorders.
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